2:24 PM
 | 
Feb 12, 2018
 |  BC Extra  |  Company News

FDA, EMA, Japan reviewing Pfizer's lorlatinib for NSCLC

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to an NDA for lorlatinib (PF-06463922) to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in patients previously...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >